SECTOR:
Other therapeutics
FUND/VEHICLE:
Pivotal US
INVESTMENT DATE:
2018
GEOGRAPHY:
North America
STATUS CURRENT/FORMER INVESTMENT:
Existing
WEBSITE:
Inozyme is a biotechnology company committed to developing novel medicines for the treatment of rare metabolic diseases of calcification. The company was founded in 2016 with technology licensed from Yale University.